<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157079</url>
  </required_header>
  <id_info>
    <org_study_id>160101</org_study_id>
    <nct_id>NCT00157079</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders</brief_title>
  <official_title>A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of Immune Globulin Intravenous&#xD;
      (Human), 10% (IGIV 10%) in subjects with primary immunodeficiency disorders.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2002</start_date>
  <completion_date type="Actual">December 16, 2003</completion_date>
  <primary_completion_date type="Actual">December 16, 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Mean number of acute serious bacterial infections per participant per year</measure>
    <time_frame>Throughout the study period of 18 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">61</enrollment>
  <condition>Primary Immunodeficiency Diseases (PID)</condition>
  <condition>Immune Thrombocytopenic Purpura (ITP)</condition>
  <condition>Kawasaki Syndrome</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immune Globulin Intravenous (Human), 10%</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained from either the subject or the subject's legally&#xD;
             acceptable representative prior to any study-related procedures and study product&#xD;
             administration&#xD;
&#xD;
          -  Diagnosis of a PID disorder as defined by World Health Organization criteria for which&#xD;
             the subject has been receiving a regimen of IGIV infusions every 21 to 28 days over a&#xD;
             period of at least 4 months pre-study at a dose of 300-600 mg/kg body weight&#xD;
&#xD;
          -  Subjects &gt; 24 months of age&#xD;
&#xD;
          -  A negative serum pregnancy test for any female subject who is of childbearing&#xD;
             potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects sero-positive at enrollment for one or more of the following: hepatitis B&#xD;
             surface antigen (HBsAg), antibodies to hepatitis C virus (HCV), antibodies to human&#xD;
             immunodeficiency virus (HIV) Types 1 or 2&#xD;
&#xD;
          -  Subjects with levels of alanine amino transferase (ALT) and aspartate amino&#xD;
             transferase (AST) &gt; 2.5 times the upper limit of normal for the testing laboratory. An&#xD;
             AST &gt; 2.5 times the upper limit of normal is allowable, if the ALT does not exceed the&#xD;
             upper limit of the reference range for the testing laboratory&#xD;
&#xD;
          -  Subjects with neutropenia (defined as an ANC &gt;= 1,000/mm3)&#xD;
&#xD;
          -  Subjects with serum creatinine levels greater than two times the upper limit of normal&#xD;
             for age and gender&#xD;
&#xD;
          -  Subjects with malignancy or a history of malignancy&#xD;
&#xD;
          -  Subjects who received any blood or blood product exposure other than an IGIV and/or&#xD;
             immune serum globulin (ISG) preparation within the 6 months prior to study entry&#xD;
&#xD;
          -  Subjects with an ongoing history of hypersensitivity or persistent reactions&#xD;
             (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IGIV&#xD;
             and/or ISG infusions&#xD;
&#xD;
          -  Subjects with selective complete IgA deficiency&#xD;
&#xD;
          -  Subjects with moderate levels of anti-IgA antibodies (&gt;150), or subjects with lower&#xD;
             anti-IgA antibodies who are naive to IGIV treatment. (Subjects with lower levels of&#xD;
             IgA antibodies, whom the investigators know to have tolerated IgA containing IGIV&#xD;
             preparations in the past, may be included if the investigator is comfortable with&#xD;
             this)&#xD;
&#xD;
          -  Subjects receiving antibiotic therapy for the treatment of infection within 30 days&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Subjects who receive prophylactic antibiotics as part of their care regimen&#xD;
&#xD;
          -  Subjects participating in another clinical study involving an investigational product&#xD;
             or device within 30 days prior to study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children´s Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304-8786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Allergy and Clinical Research Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates of the Palm Beaches</name>
      <address>
        <city>North Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida; Asthma, Allergy &amp; Immunology CRU</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - St. Lukes Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children´s Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma &amp; Immunology Assoc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Center</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center, Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Allergy/Immunology Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>August 22, 2021</last_update_submitted>
  <last_update_submitted_qc>August 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PID</keyword>
  <keyword>Immunodeficiency</keyword>
  <keyword>Immune Thrombocytopenic Purpura (ITP)</keyword>
  <keyword>Kawasaki syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucocutaneous Lymph Node Syndrome</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

